
    
      This is a randomized double blind placebo controlled flexible dose 12 week study. Following
      screening, subjects will receive their first dose of study medication following completion of
      AUASS questionnaire on the first day of radiation treatment (baseline) and will continue for
      twelve weeks. Subjects will be started on 5 mg of study medication. The AUASS will be
      completed at baseline, weeks 4, 8 and 12. A 16 week visit conducted over a phone interview.
    
  